Загрузка...
5HT-2c AGONIST LORCASERIN DECREASES CANNABIS SELF-ADMINISTRATION IN DAILY CANNABIS SMOKERS
There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2c agonist, lorcaserin, attenuates cue-induced reinstatement of THC-seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory...
Сохранить в:
| Опубликовано в: : | Addict Biol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225547/ https://ncbi.nlm.nih.gov/pubmed/33389797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/adb.12993 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|